Figure 4.

Numerous ferroptosis events induced by A-GSP can be reversed by ferrostatin-1. (A) Ferrostatin-1 and A-GSP were mixed with concentrations of 10 μmol/L and 1,000 μg/mL, respectively. Cells were treated for 72 h (All related experiments with ferrostatin-1 added in this figure have the same treatment conditions). Changes in Fe²⁺ content in SCC15 and SCC25 cells were detected; (B) Ferrostatin-1 reverses the increase in intracellular MDA content caused by A-GSP; (C) In the Liperfluo experiment, A-GSP-induced increase in intracellular lipid peroxides can be alleviated by ferrostatin-1 (Scale bars are 20 μm and 5 μm, respectively); (D) Statistical analysis of Liperfluo experimental results; (E) A-GSP-induced decrease in intracellular GSH content can be reversed by ferrostatin-1; (F) Changes in ATP content of tumor cells induced by A-GSP were reversed by ferrostatin-1; (G) A-GSP-induced massive accumulation of intracellular ROS can be alleviated by ferrostatin-1; (H) Statistical results of ROS fluorescence intensity; (I) Changes in A-GSP-induced ferroptosis gene can be blocked by ferrostatin-1. A-GSP, aqueous-soluble sporoderm-removed G. lucidum spore powder; MDA, malondialdehyde; ROS, reactive oxygen species. **, P<0.01; ***, P<0.001; ****, P<0.0001.